## **CLAIMS**

Claims 1-8. (Canceled)

9. (Currently amended) A method of inhibiting the proliferation of cancer cells in a subject comprising administering, to the subject, an effective amount of at least one isolated peptide having a sequence selected from the group consisting of:

Cys Val His Ala Tyr Arg Ala (SEQ ID NO:2);

Cys Val His Ala Phe Arg Ser (SEQ ID NO:3); and

Cys Val His Ser Phe Arg Ala (SEQ ID NO:8);

wherein the peptide sequence exhibits an antiproliferative activity.

- 10. (Original) The method of claim 9, where the cancer cells are breast cancer cells.
- 11. (Original) The method of claim 9, where the cancer cells are lung cancer cells.
- 12. (Original) The method of claim 9, where the cancer cells are colon cells.
- 13. (Original) The method of claim 9, where the cancer cells are melanoma cells.
- 14. (Original) The method of claim 9, where the cancer cells are leukemia cells.

15-21. (Canceled)

22. (Currently amended) An isolated peptide selected from the group consisting of:

Cys Val His Ala Tyr Arg Ser (SEQ ID NO:1);

Cys Val His Ala Tyr Arg Ala (SEO ID NO:2):

Cys Val His Ala Phe Arg Ser (SEQ ID NO:3); and

Cys Val His Ala Phe Arg Ala (SEQ ID NO:4);

Cys-Val His Ser Tyr-Arg Ser (SEQ ID NO:5);

Cys Val His Ser Tyr Arg Ala (SEQ ID NO:6);

Cys Val His Ser Phe Arg Ser (SEQ ID NO:7);

Cys Val His Ser Phe Arg Ala (SEQ ID NO:8):

Cys Val His Thr Tyr Arg Ser (SEQ ID NO:9):

Cys Val His Thr Tyr Arg Ala (SEO ID NO:10):

Attorney Docket No. 120785.00311

Serial No. 10/670,490 Inventor: Barnea

Cys Val His Thr Phe Arg Ser (SEQ ID NO:11); and Cys Val His Thr Phe Arg Ala (SEQ ID NO:12).

23-24. (Canceled)

25. (Currently amended) A composition comprising an excipient and at least one isolated peptide consisting essentially of:

Cys Val His Ala Tyr Arg Ser (SEQ ID NO:1);
Cys Val His Ala Tyr Arg Ala (SEQ ID NO:2);
Cys Val His Ala Phe Arg Ser (SEQ ID NO:3); or
Cys Val His Ala Phe Arg Ala (SEQ ID NO:4);
Cys Val His Ser Tyr Arg Ser (SEQ ID NO:5);
Cys Val His Ser Tyr Arg Ala (SEQ ID NO:6);
Cys Val His Ser Phe Arg Ser (SEQ ID NO:7);
Cys Val His Ser Phe Arg Ala (SEQ ID NO:8);
Cys Val His Thr Tyr Arg Ser (SEQ ID NO:9);
Cys Val His Thr Tyr Arg Ala (SEQ ID NO:10);
Cys Val His Thr Phe Arg Ser (SEQ ID NO:11); or
Cys Val His Thr Phe Arg Ala (SEQ ID NO:12).

26. (Previously presented) A method of inhibiting proliferation of cancer cells in a subject comprising administering to the subject an effective amount of at least one isolated peptide consisting essentially of:

Cys Val His Ala Tyr Arg Ala (SEQ ID NO:2); Cys Val His Ala Phe Arg Ser (SEQ ID NO:3); or Cys Val His Ser Phe Arg Ala (SEQ ID NO:8).

- 27. (Canceled)
- 28. (Currently amended) An isolated peptide having a sequence selected from the group consisting of:

Cys Val His Ala Tyr Arg Ala (SEQ ID NO:2); Cys Val His Ala Phe Arg Ser (SEQ ID NO:3); and Attorney Docket No. 120785.00311 Scrial No. 10/670,490 Inventor: Barnea

Cys Val His Ser Phe Arg Ala (SEQ ID NO:8); wherein the sequence peptide exhibits an antiproliferative activity.

29. (Currently amended) A composition comprising an excipient and at least one isolated peptide having a sequence selected from the group consisting of:

Cys Val His Ala Tyr Arg Ala (SEQ ID NO:2); Cys Val His Ala Phe Arg Ser (SEQ ID NO:3); and Cys Val His Ser Phe Arg Ala (SEQ ID NO:8);

wherein the sequence peptide exhibits an antiproliferative activity.

30. (Currently amended) A composition consisting essentially of an isolated peptide selected from the group consisting of:

Cys Val His Ala Tyr Arg Ser (SEQ ID NO:1);
Cys Val His Ala Tyr Arg Ala (SEQ ID NO:2);
Cys Val His Ala Phe Arg Ser (SEQ ID NO:3); and
Cys Val His Ala Phe Arg Ala (SEQ ID NO:4);
Cys Val His Ser Tyr Arg Ser (SEQ ID NO:5);
Cys Val His Ser Tyr Arg Ala (SEQ ID NO:6);
Cys Val His Ser Phe Arg Ser (SEQ ID NO:7);
Cys Val His Ser Phe Arg Ala (SEQ ID NO:8);
Cys Val His Thr Tyr Arg Ser (SEQ ID NO:9);
Cys Val His Thr Tyr Arg Ala (SEQ ID NO:10);
Cys Val His Thr Tyr Arg Ser (SEQ ID NO:11); and
Cys Val His Thr Phe Arg Ala (SEQ ID NO:12).